NASDAQ: TVGN · Life Sciences · 5 alerts · CIK 1860871
Share price
$6.22Close, Nov 16
Market cap
$40.5M
Shares outstanding
6.51MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Tevogen Inc. filings on SEC EDGAR ↗
Tevogen Inc. reported a net loss of $18.2 million for the nine months ended September 30, 2026, compared to $21.6 million in the prior year period. The company continues to operate with a significant stockholders' deficit of $11.3 million and relies on financing activities, including a $3.0 million loan and $3.0 million from pre-funded warrants, to fund its biotechnology and AI initiatives.
Susan Podlogar resigned from the Board of Directors of Tevogen Inc. effective November 2, 2026. Following the resignation, the Board reduced its size from six to five members and appointed current director Lindee Goh to the Audit Committee.
Tevogen $36M Debt Financing with The Patel Family, LLP
Tevogen Inc. amended its unsecured line of credit with The Patel Family, LLP, extending the borrowing period to May 31, 2029, and fixing the share price for debt repayment at $7.40 per share. Following the amendment, the company issued approximately 1.02 million shares to repay the entire $7.4 million outstanding principal balance and accrued interest, effectively eliminating its current debt liabilities.
Tevogen Inc. received written notice from Nasdaq confirming it has regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A). This follows a previous notice regarding the market value of publicly held shares, and with both requirements now satisfied, all related Nasdaq compliance matters are closed.